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1, 2005 through December 31, 2011 for patients with commercial or employer-
sponsored supplemental Medicare insurance. Bevacizumab claims were 
excluded if the claim had a diagnosis related to macular degeneration or other 
eye disease. Claims for both drugs were excluded from the payment analysis if 
the reimbursed amount was less than $100. All claims were identified as 
occurring in an office-based setting (OBS), an outpatient hospital setting (OHS) or 
other setting. RESULTS: The percent of bevacizumab claims occurring in OHS 
increased from 6 to 37% among Medicare claims, and from 15 to 42% among 
commercial claims from 2005 to 2011. For trastuzumab, the increases were 9 to 
33%, and 17 to 37% in Medicare and commercial claims, respectively. Median 
bevacizumab reimbursement increased 56% ($3000 to $4681) for OBS and 125% 
($3438 to $7739) for OHS from 2005 to 2011 in commercial claims. For Medicare 
claims, the increases were 88% ($2284 to $4284) and 111% (2284 to $4827) for OBS 
and OHS, respectively. For trastuzumab commercial claims, median 
reimbursement increased 47% ($2037 to $2996) and 88% ($2749 to $5171) for OBS 
and OHS; while for Medicare the increases were 68% ($1697 to $2854) and 67% 
($1704 to $2838), respectively. CONCLUSIONS: The shift in chemotherapy 
administration from OBS to OHS and related growth in reimbursement for 
outpatient hospital settings relative to office settings has implications for the 
growth in cancer costs over the past decade. Further research is warranted to 
understand the drivers of the shift in location and whether future policies should 
address reversing the shift.  
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OBJECTIVES: To analyze the cost of care in oncology inpatients in Brazilian 
private hospitals and their spending on medicine (chemotherapy and palliative 
care). METHODS: We selected patients who consume antineoplastic medicines 
in Orizon database (16 million lifes) within a 12-month period and analyzed their 
medical bills, appointments and hospitalizations (direct costs) and also 
medicines for palliative treatment. RESULTS: We identified 1244 patients who 
consume an annual average of R$ 6,342.51 in outpatient use of anticancer drugs 
per patient and their medical bills US$30,320.78 in expenses with a mean 
hospital stay of 4.60 days with 4, 48 consultations per patient to the cost of 
R$210.56 and the cost of medicines for palliation of R$6,277.16 (regulators of bone 
metabolism, corticosteroids, antidepressants, anti-inflammatories, diuretics, 
antiemetics, anticonvulsants, analgesics, vitamins and antispasmodics) 
CONCLUSIONS: The direct costs of cancer patients is not restricted only hospital 
infusions and their admissions, but also outpatient expenditures such as oral 
medications and palliative treatments.  
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OBJECTIVES: The prognosis of melanoma patients with brain metastases is poor, 
with median overall survival of approximately 4-5 months. This is the first study 
aiming at quantifying medical resources utilization and direct health care costs 
associated with brain metastases among metastatic melanoma patients in the 
U.S. METHODS: A retrospective pre-post design was implemented using data 
from the Truven MarketScan claims database (2000Q1-2011Q3). Patients with ≥1 
diagnosis of melanoma (ICD-9-CM: 172-173, 198.2), ≥1 diagnosis of brain 
metastases (ICD-9-CM: 198.3), and ≥18 years as of the first observed brain 
metastases diagnosis (index date) were identified. The pre-period was defined as 
the 6 months prior to the index date and post-period as the period following the 
index date up to the earliest of 12 months, recorded death, or loss to follow up. 
All-cause and brain metastasis-related medical resources and health care costs 
were compared on a per patient per month (PPPM) basis between the pre- and 
post-periods. RESULTS: The study population consisted of 6076 patients; mean 
(SD) age was 63.4 (13.4) years and 57.6% males. Significant differences were 
observed between the post- and pre-period in mean all-cause PPPM 
hospitalizations (0.21 vs. 0.08), emergency department visits (0.12 vs. 0.08), and 
outpatient visits (4.48 vs. 3.74) (p<.0001 for all). Similar results were found for 
brain metastasis-related hospitalizations (0.15 vs. 0.04), emergency department 
visits (0.02 vs. 0.01), and outpatient visits (2.00 vs. 1.17) (p<.0001 for all). 
Significant post- vs. pre-period differences were also observed in the PPPM all-
cause health care costs (total: $14,489 vs. $7,277; inpatient: $6,330 vs. $1,900; 
outpatient: $6,609 vs. $4,449; p<.0001 for all) and brain metastasis-related costs 
(total: $6,542 vs. $1,933; inpatient: $2,976 vs. $472; outpatient: $3,451 vs. $1,413; 
p<.0001 for all). CONCLUSIONS: The economic burden associated with brain 
metastases in melanoma is significant and underscores the need for newer 
therapies improving outcomes among these patients.  
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OBJECTIVES: Prolonged air leaks (PAL) lasting >5 days occur in up to 50% of all 
patients undergoing lung volume reduction surgery (LVRS); resulting in increased 
length of stay (LOS), patient morbidities, and health care costs. We sought to 
map care path options for the management of PAL following LVRS among 
emphysematous patients, and to report estimates of associated costs. 
METHODS: Peer-reviewed English language articles from January 2000 – 
September 2012 were searched using pre-identified terms. A typical care path for 
a male smoker with emphysema was mapped from diagnosis to removal of chest 
tube after LVRS. Parameters extracted from the identified articles were 
country/region, year, type of study, type of procedure [open vs. video-assisted 
thoracoscopic surgery (VATS)], number of patients, cost, LOS and complication 
rates. RESULTS: The care path captured treatment events from diagnosis of 
nodules to post-surgical follow up care. PAL treatment options included the 
Heimlich valve, autologous blood patch or both prior to discharge. Eleven studies 
reporting cost data for 4,945 VATS procedures and 18,033 open procedures were 
identified. LOS [3.0 – 17.3 days (VATS) versus 5.0 to 23.8 days (open)], hospital 
costs [US unadjusted: $10,084 to $23,826 (VATS) versus $12,119 - $25,125 (open)] 
and complication rates were lower for VATS versus open procedures. Similar 
cost differences were reported in Korea, Japan and China. Post-discharge care 
and cost of patients with PAL were driven by the utilization of home health care, 
increased pain management costs, more frequent doctor visits and delayed 
return to work. CONCLUSIONS: There is wide variability in the care path options 
associated with management of PAL and associated complications during LVRS 
in emphysema patients. VATS appears to have a positive health care utilization 
and cost advantage versus open procedures globally. Further analyses are 
needed to quantify the true cost of care associated with managing PAL in LVRS 
patients.  
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OBJECTIVES: To evaluate the cost-effectiveness of cabazitaxel in 2L metastatic 
castration resistant prostate cancer (mCRPC) patients who progressed after 
docetaxel (D) from the Swedish health care perspective in a subgroup of the 
TROPIC trial (NCT00417079) METHODS: A Markov cohort based cost effectiveness 
model was used. Transition rates between the health states representing mCRPC 
disease progression (stable, progression, death) were estimated based on 
progression of disease and survival rates from the TROPIC trial. The efficacy and 
safety data is based on the results of the TROPIC trial, which compares 
cabazitaxel plus prednisone to mitoxantrone plus prednisone in patients 
previously treated with docetaxel. Resource inputs were obtained from 
literature, hospital data and key opinion leaders. The subgroup is defined as 
those patients who initially responded to D but experienced disease progression 
<3 months since last D dose. At the time of the trial, the combination of 
Mitoxantrone (M) and Prednisone (P) was considered to be an appropriate second 
line comparator. Hence, in the base-case, M + P is the main comparator, in 
accordance with the TROPIC trial design. In addition, an indirect comparison 
versus P alone was carried out. Costs in added life years were added in the model 
to follow the societal perspective of Swedish health care system. RESULTS: In 
the base case analysis, total costs were estimated to be 699 176 SEK for 
Cabazitaxel, 320 491 SEK for M+P and 302 726 SEK for P alone. For the TROPIC 
subgroup, the ICER for C+P vs M+P was 943 270 SEK/QALY, ICER for C+P vs P 
alone was 990 903 SEK/QALY . Based on historical decision making by TLV, the 
threshold in Sweden is 1,000,000 SEK/QALY. CONCLUSIONS: Cabazitaxel appears 
to be a cost effective option compared with mitoxantrone and prednisone in the 
subgroup of TROPIC in Swedish health care setting.  
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OBJECTIVES: To evaluate the cost-effectiveness of posaconazole versus 
fluconazole/ itraconazole in invasive fungal infection (IFI) prevention among 
patients with acute myelogenous leukemia (AML) or myelodysplastic syndromes 
(MDS) and at high risk of IFI due to chemotherapy-induced neutropenia in 
Singapore. METHODS: A decision-analytic model previously developed for the US 
and other countries was adapted to Singapore, to estimate the cost-effectiveness 
of antifungal prophylaxis with posaconazole compared to fluconazole/ 
itraconazole among AML or MDS patients at high risk of IFI. Patients were 
assumed to receive prophylaxis with posaconazole or fluconazole/ itraconazole. 
Probabilities of IFI, IFI-related death, and other cause death within 100 days of 
follow-up were estimated from clinical trial data. Trial results were extended to a 
lifetime horizon by modeling cancer-specific mortality, estimated from 
published sources, in one-month Markov cycles. Prophylaxis and IFI treatment 
costs were estimated using data obtained from two hospitals in Singapore. Model 
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outputs include total costs (Singapore dollars (SGD); 1 SGD=0.82 USD), IFIs 
avoided, life-years saved, and incremental cost-effectiveness of posaconazole 
versus fluconazole/ itraconazole. A probabilistic sensitivity analysis (PSA) was 
conducted, where probabilities of IFI, IFI-related death, and 100-day other cause 
mortality were assigned beta distributions from trial data. RESULTS: Total costs 
of prophylaxis with fluconazole/ itraconazole and posaconazole were SGD 4,475 
and SGD 4,999, respectively. Corresponding health outcomes were 0.11 and 0.05 
IFIs and 2.44 and 2.51 life-years. Incremental cost-effectiveness ratios for 
posaconazole were SGD 8,150 per IFI avoided and SGD 7,526 per life-year saved. 
Posaconazole was cost-effective compared to fluconazole/ itraconazole in 94% of 
PSA simulations at a threshold of SGD 80,000 (commonly cited threshold in 
Singapore). CONCLUSIONS: Use of posaconazole in place of fluconazole/ 
itraconazole for prevention of IFIs in a high-risk neutropenic population is cost-
effective at a willingness-to-pay threshold of SGD 80,000 per life-year saved in 
Singapore.  
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OBJECTIVES: To examine the overall incremental cost and survival benefit 
associated with the receipt of second line chemotherapy/biologics (Tx2) among 
elderly Medicare metastatic colon cancer (mCC) patients who had received first 
line chemotherapy/biologics treatment (Tx1). METHODS: Elderly (66+) SEER-
Medicare patients diagnosed with mCC in 2003-2007 were identified and 
followed until death or 12/31/09. The analysis was restricted to patients who 
received any chemotherapy/biologics treatment. Cox regression and partitioned 
least squares regression were utilized to obtain the incremental survival benefit 
and the overall incremental cost associated with the receipt of Tx2 within a five-
year period, respectively. The regressions controlled for patient demographic 
and clinical characteristics including cancer related measures, Charlson 
comorbidity index and proxy for poor performance status. Bootstrapping was 
used to produce 95% confidence intervals (CI). RESULTS: Of the 3,266 elderly 
Medicare mCC who received Tx1, 2,744 (84%) died within the observation period; 
1,440 (44%) received Tx2; 274(8%) received subsequent treatments. The 
incremental survival benefit associated with the receipt of Tx2 was 0.631 years 
(CI: 0.517 − 0.761), and the associated overall incremental cost was $107,027 (CI: 
93,401 − 120,887). The incremental cost-effectiveness ratio for Tx2 was $169,722 
per life year gained (CI: 137,139 − 208,134). CONCLUSIONS: The estimated 
survival benefit of receiving second line chemotherapy/biologics treatment 
ranges from 6 to 9 months, which is consistent with evidence from clinical trials. 
This improved survival was associated with costs that are slightly above 
$100,000.  
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BACKGROUND: Metastatic melanoma (MM) is the deadliest form of skin cancer. 
It’s associated with high mortality with a median overall survival (OS) of 6 to 9 
months. Ipilimumab is the first agent to improve the survival of metastatic 
melanoma patients and to provide long-term benefit to a proportion of patients 
treated within phase II/III studies and expanded access programs. OBJECTIVES: 
To evaluate the cost-effectiveness of ipilimumab in previously treated patients 
for advanced melanoma compared to Best Supportive Care (BSC) from a 
Portuguese national payer perspective. METHODS: A three-state Markov model 
with stable disease, progression and death was developed. The model assumed 
three-week cycles, and the analysis assumed a lifetime time horizon. Costs and 
consequences were discounted at 5%. Patient-level data from the pivotal Phase 
III MDX010-20 trial was used to describe the survival of ipilimumab 3mg/kg and 
BSC (based on the gp100 arm of the trial). Extrapolation methods were used to 
model long-term survival beyond the trial. Clinical practice and resource 
utilization were assessed from a survey of Portuguese oncologists and 
dermatologists. Unit costs were obtained from official sources and outcomes 
were described in life years (LY) gained. One-way and probabilistic SA were also 
undertaken. RESULTS: Ipilimumab was associated with an additional gain of 1.29 
LY when compared to BSC, with an incremental cost-effectiveness ratio of 
€53,579/LY. Results were most sensitive to different survival extrapolation 
assumptions and the treatment cost. Probabilistic SA showed a >95% likelihood 
that ipilimumab is cost-effective at a willingness to pay threshold of €59,000/LY. 
CONCLUSIONS: Ipilimumab offers a significant survival benefit when compared 
with BSC, but at a higher cost. Given the high unmet need, small number of 
advanced melanoma patients and robust sensitivity analyses; it is likely that 
ipilimumab represents a cost-effective treatment for previously treated 
advanced melanoma patients in Portugal.  
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OBJECTIVES: Dosing of chemotherapy regimens using 5-fluorouracil (5-FU) in 
patients with metastatic colorectal cancer (mCRC) is based on body surface area 
(BSA), which has been shown to yield suboptimal plasma 5-FU levels. 
Pharmacokinetic (PK) monitoring of 5-FU shows promise in terms of optimal 
dosing, but its cost-effectiveness is unknown. This study performs a cost-
effectiveness analysis of PK dosing versus BSA dosing of 5-FU among patients 
with mCRC in the UK. METHODS: A decision tree model was used to perform a 
counterfactual simulation of the cost-effectiveness of PK versus BSA dosing of 5-
FU in standard chemotherapy regimens for mCRC in the UK population. All 
patients were assumed to receive first-line therapy for 6 or 12 cycles or until 
progression, after which they received standard post-first-line chemotherapy 
and subsequent palliative care until death. Costs were estimated from the 
perspective of the national health system as payer, were drawn from the 
literature and publically available national unit cost estimates. Effectiveness was 
quality adjusted life years (QALY), with utilities estimated from the literature. 
Discounting was performed at 3% per year. Incremental cost-effectiveness ratios 
comparing PK to BSA dosing were computed for the six most common 
chemotherapy regimens that utilize 5-FU. RESULTS: The average ICER across all 
regimens and weighted by their current distribution was £7,336 per incremental 
QALY gained. The ICER for lifetime discounted incremental cost per incremental 
QALY for PK versus BSA dosing was £3,467 for a FOLFOX4 regimen, £3,594 for a 
FOLFOX6 regimen, £23,428 for FOLFIRI, £3,508 for FOLFOX6 + bevacizumab, 
£21,874 for FOLFIRI + bevacizumab, and £28,862 for a 5-FU + leucovorin 
chemotherapy regimen. CONCLUSIONS: PK dose management of 5-FU based 
chemotherapy regimens for patients with mCRC appears cost-effective from a 
UK national payer perspective. Cost-effectiveness was driven in part by better 
efficacy and reduced adverse events.  
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OBJECTIVES: Metastatic renal cell carcinoma (mRCC) is one of the most common 
adult malignancies. Overall survival (OS) without treatment ranges from 6 to 12 
months and in Ecuador, 269 patients were estimated in 2008 with mRCC. The 
aim of this study was to assess the cost-effectiveness of first-line therapies for 
patients with mRCC from the payer’s perspective over five years. METHODS: 
Cost–effectiveness and cost-utility analyses were developed using a Markov 
model to compare within a six-week cycle: sunitinib (50mg/day, four weeks 
treatment and two week off) versus sorafenib (800mg/day) and bevacizumab 
(10mg/kg bi-weekly) + IFN (9MU every 3 weeks). Model contains 5 health states 
(first-line treatment-no progression-, second-line treatment, palliative care, 
death due to mRCC and death due to other causes). It simulates overall costs, 
progression free-years (PFY), life years gained (LYG) and Quality Adjusted Life 
Years (QALYs) gained. Transition probabilities/utilities were obtained from 
previous published trials. Resource use and costs data was obtained from 
National Ecuadorian Health Formulary (Minister of Health 2012) which includes 
costs data from MoH Centers, IESS, Military Hospital and Police Hospital). Official 
Epi data from the Ecuadorian Institute of Social Security (IESS), Globocan, SOLCA, 
and other local institutions were considered. Both costs and effectiveness were 
discounted using a 5% annual rate. RESULTS: First-line treatment with sunitinib 
showed the highest PFY, LYG and QALYs (1.27; 2.35; 1.56 years, respectively) 
followed by bevacizumab+IFN- (1.11; 2.22; 1.45 years) and sorafenib (0.81; 2.26; 
1.43 years). Expected health care costs related to sunitinib resulted lower: 
US$72,599 versus US$111,286 for sorafenib and US$ 192,208 for 
bevacizumab+IFN. Other costs related with therapy administration, caregivers 
and adverse events were also lower with sunitinib. Probabilistic sensitivity 
analyses showed robustness of these results CONCLUSIONS: Sunitinib is cost–
saving among the new agents for patients with mRCC, achieving higher clinical 
outcomes and lower costs in Ecuador.  
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OBJECTIVES: Prevention of the painful, debilitating and costly skeletal 
complications of BM is an important therapy goal. We aimed to evaluate the 
cost-effectiveness of denosumab (120mg Q4W) versus ZA (4 mg Q4W) in the 
prevention of SRE in prostate cancer patients with BM from the public health 
care setting in Mexico. METHODS: A three-state (on/off treatment and dead) 
lifetime Markov model with 4-week cycles was developed in order to estimate 
the incremental cost-effectiveness ratio (ICER) per SRE avoided. The real-world 
SRE rates in ZA-treated patients were derived from a large commercial database 
and used together with the trial-based treatment effect for denosumab versus 
ZA to estimate the denosumab SRE rate. ZA acquisition cost was gathered from 
local public tenders. Unit cost for medical consultation, drug´s administration 
and laboratory tests were obtained from official lists. Diagnosis-related group 
data were used to assess the costs attributable to SRE. Costs are expressed in 
2012 Mexican pesos. Overall survival was similar between the treatment arms of 
